Recentin fails to meet primary endpoint in cancer trial

Monday 8 March 2010

AstraZeneca Plc said that its candidate drug, Recentin (cediranib), for patients with first-line metastatic colorectal cancer, failed to meet its primary endpoint of non-inferiority in progression-free survival in a Phase 2/3 trial.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom